Executive readout · one minute
What the filings say
- 8-K earnings release · filed Oct 29, 2026
- Penumbra Inc reported third-quarter 2026 revenue of $410.1 million, up 15.6%, global thrombectomy revenue of $279.2 million, up 18.1%, and net income of $42.3 million; pending acquisition by Boston Scientific Corporation led it to withhold full year 2026 guidance.
- 10-Q report · filed Oct 29, 2026
- Penumbra agreed to be acquired by Boston Scientific Corporation for approximately $14.5 billion, with each share valued at $374 and closing expected in early 2027. Revenue for the nine months ended September 30, 2026 increased 15.4% to $1,174.9 million.
The audio replay and transcript follow the call.